Camrelizumab with chemotherapy after surgery for lymph node-positive cervical cancer
Tests camrelizumab plus chemotherapy after surgery in adults with cervical cancer.
Plain-language title generated from the registry record
Registry title: Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial
Key facts
- Where
- Hangzhou, ChinaSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women aged 18 to 70 with cervical cancer. Their cancer was removed by surgery, and lymph nodes were found to contain cancer.
- Age
- 18 to 70 years
- Sex
- Women only
- Disease stage
- Cervical cancer stage FIGO2018 IIIC1p or IIIC2p after radical surgery
- Earlier treatment
- Radical surgery for cervical cancer. People who had earlier treatment with immune checkpoint inhibitors cannot join.
- Biomarker or test result
- PD-L1 expression must be positive
Main reasons for not taking part
- Cancer cells in the parametrium or at the surgical margin
- Radical surgery was incomplete
- Tumour lesions left behind
- Active autoimmune disease, or autoimmune disease needing systemic treatment
- Earlier treatment with immune checkpoint inhibitors
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07167160, who can take part
Where in China
- Women's hospital school of medicine Zhejiang UniversityHangzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Women's Hospital School Of Medicine Zhejiang University
- Trial code
- NCT07167160
- Record updated
- 18 December 2025
- Original description
Efficacy evaluation of camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery.Read full original descriptionShow less
Camrelizumab Combined With Chemotherapy for Adjuvant Treatment of Cervical Cancer Patients With Pathologically Confirmed Lymph Node Positivity After Stage Surgery: A Prospective, Single-Arm, Multicenter, Phase II Clinical Trial
Efficacy evaluation of camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery.
Inclusion: Patients with cervical cancer staged FIGO2018 IIIC1p or IIIC2p after radical surgery; Positive PD-L1 expression; ECOG score ≤1.
Exclusion: Positive parametrium or surgical margin; Incomplete radical surgery; Previous treatment with immune checkpoint inhibitors; Active autoimmune disease or autoimmune disease requiring systemic treatment; Residual target lesions.